A Study to Evaluate the Safety and Pharmacokinetics of BX-001N in Healthy Participants

Summary

This is a randomized, double-blind, placebo-controlled, single and multiple ascending dose, Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of BX-001N after intravenous administration in approximately 64 healthy participants

Timeline

Start

2023-11-17

Primary completion

2024-11-06

Completion

2024-11-06

Drugs

Indications